id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
160,,,,,,,,,,,,,,,2024-06-03T16:33:41+06:00,BSH - H12101137709,Left,,,,"Started NACT with ddAC, received 3 cycle in ddAC schedule> , 4 cycle upto 10.02.2021.
Cycle 8 with Docetaxel + Trastuzumab 3 weekly completed on 03.05.21> Maintenance Trastuzumab
completed on 31.01.2022",2024-01-21,,2024-01-21,,2023-05-02,2023-05-02,2023-05-02,Breast,155,Upper middle class,BSBSC-240000155,JOYNAB,1768970979,1956-01-21,Female,,,,,Dr Ferdous Ara Begum,BSH,2.0,,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,"C50.9- Breast, unspecified",Breast,Left,,,Stable,Alive,CR,,,,CR,,,,,,,CR,,,,,,,,,,
